Abstract: Malignant melanoma is the most common fatal skin tumor. Molecular targeted drugs effect on advanced and metastatic melanoma is remarkable, including mitogenactivated protein kinase (MAPK) inhibitors, phosphatidylinositide 3kinase (PI3K) inhibitors, receptor tyrosine kinase (TKR) inhibitors and vascular endothelial growth factor (VEGF) inhibitors. Vemurafenib and Dabrafenib, as the representative of the vRaf murine sarcoma viral oncogene homolog B1 (BARF) kinase inhibitors, play important roles for malignant melanoma. However, the primary or acquired drug resistance to this drug limits its clinical use. At present, some new molecular targeted drugs such as Trametinib, representative of mitogenactivated extracellular signalregulated kinase (MEK) inhibitors, have been used and patients can benefit from the treatment. Studies on the mechanism of drug resistance and the combination of multiple target drugs also provide more potential for individualized molecular targeted therapy of malignant melanoma.

Key words: Melanoma, Drug therapy, Enzyme inhibitors, Drug resistance